ArticleGland surgery2025
Value of dynamic contrast-enhanced ultrasound in predicting cervical lymph node metastasis in papillary thyroid carcinoma patients with Hashimoto's thyroiditis.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hashimoto's thyroiditis (HT) and papillary thyroid carcinoma (PTC) commonly coexist. An accurate assessment of cervical lymph node metastasis (CLNM) is crucial for determining treatment options and predicting prognosis. However, traditional examination methods have certain limitations. This study aimed to investigate the potential utility of dynamic contrast-enhanced ultrasound (DCE-US) using VueBox Methods: A retrospective analysis was performed on the clinicopathological data and ultrasound characteristics of 180 thyroid cancer patients who underwent either biopsy or surgery from January 2022 to November 2023. The dataset was partitioned into training and validation sets with a 6:4 ratio. Statistical analyses, including Results: The Model 3 exhibited superior performance compared to Models 1 and 2. Specifically, in the training set, Model 3 achieved an area under the curve (AUC) value of 0.924 [95% confidence interval (CI): 0.857-0.966], and in the validation set, the AUC value was 0.905 (95% CI: 0.813-0.962). These values were significantly higher (P<0.05) than those of Model 1, which had a training AUC of 0.724 (95% CI: 0.630-0.806) and a validation AUC of 0.677 (95% CI: 0.557-0.783), as well as Model 2, with a training AUC of 0.854 (95% CI: 0.773-0.915) and a validation AUC of 0.797 (95% CI: 0.683-0.883). Moreover, DCA indicated that Model 3 provided a greater net benefit than Models 1 and 2 in both the training and validation cohorts. Conclusions: The use of VueBox
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.